Peptide-Based Wound Dressings
Peptide-Based Wound Dressings
5-fold MRSA reduction
Nanofiber dressings loaded with an engineered cathelicidin peptide reduced methicillin-resistant Staphylococcus aureus biofilm load by 5-fold in diabetic wound models.
Su et al., Molecular Pharmaceutics, 2019
Su et al., Molecular Pharmaceutics, 2019
View as imageChronic wounds affect an estimated 2.5% of the U.S. population and cost the healthcare system over $28 billion annually. Standard wound dressings, from gauze to foam to silver-impregnated materials, are passive barriers: they cover the wound and absorb exudate, but they do not actively fight infection, modulate inflammation, or stimulate tissue regeneration. Antibiotic-loaded dressings address infection but contribute to antimicrobial resistance, now considered among the most urgent global health threats. Peptide-based wound dressings represent a fundamentally different approach. These materials incorporate short amino acid sequences that kill bacteria through membrane disruption (a mechanism bacteria struggle to develop resistance against), recruit immune cells, promote blood vessel formation, and scaffold new tissue growth, all from within the dressing itself.[1] This article maps the full landscape of peptide wound dressing research, from antimicrobial peptide nanofibers to self-assembling hydrogels to GLP-1 agonist-driven diabetic wound repair. For detailed coverage of specific subtopics, see our articles on antimicrobial peptides in wound care, peptides for chronic wound healing, GHK-Cu in wound repair, peptides for burn treatment, and diabetic wound healing.
Key Takeaways
- Nanofiber dressings loaded with an engineered human cathelicidin peptide (17BIPHE2) reduced MRSA biofilm bacterial load by 5-fold and accelerated wound closure in a type II diabetic mouse model (Su et al., Molecular Pharmaceutics, 2019)
- A pH-sensitive peptide hydrogel killed drug-resistant biofilm bacteria and promoted wound closure to 97.6% in diabetic foot ulcer models within 14 days (Fan et al., Journal of Materials Chemistry B, 2024)
- GHK-Cu (glycyl-L-histidyl-L-lysine copper) accelerated wound healing and increased hydroxyproline content (a collagen marker) in guinea pig skin wounds compared to controls (Buffoni et al., Archives Internationales de Pharmacodynamie, 1995)
- Self-assembled peptide hydrogels achieved 96% wound closure in murine full-thickness wound models, compared to 82% for untreated controls, with enhanced collagen deposition and angiogenesis (Sharma et al., ChemBioChem, 2022)
- Liraglutide (a GLP-1 receptor agonist) accelerated diabetic wound healing through the Myo1c/Dock5 pathway, promoting fibroblast migration and angiogenesis in streptozotocin-induced diabetic mice (Zhang et al., Advanced Science, 2024)
- Healitide-GP1, a machine-learning-designed antibacterial peptide, achieved 48-52% wound closure after 24 hours and strong bactericidal activity against S. aureus and E. coli in vitro (Zare-Zardini et al., Scientific Reports, 2025)
Why Conventional Wound Dressings Fall Short
Wound healing proceeds through four overlapping phases: hemostasis (minutes), inflammation (days 1-6), proliferation (days 4-21), and remodeling (weeks to months). Chronic wounds, those that fail to progress through these phases within 4-6 weeks, stall primarily during the inflammatory phase. Persistent bacterial biofilms, excessive protease activity, and dysregulated immune signaling create a self-reinforcing cycle that conventional dressings cannot break.
Standard gauze and foam dressings maintain a moist environment and absorb fluid but do not address the biological stalling points. Silver-containing dressings and antibiotic-impregnated materials provide antimicrobial action but accelerate resistance: bacteria exposed to sub-inhibitory antibiotic concentrations in wound beds develop resistance mutations, and those mutations spread. Silver dressings are cytotoxic to fibroblasts and keratinocytes at concentrations that effectively kill bacteria, creating a tradeoff between infection control and tissue regeneration.
Peptide-based dressings bypass this tradeoff. Antimicrobial peptides kill bacteria through physical membrane disruption, a mechanism that requires bacteria to fundamentally restructure their cell membranes to develop resistance, a far higher evolutionary barrier than the single-gene mutations that confer antibiotic resistance.[2] Simultaneously, many antimicrobial peptides promote wound healing through direct effects on keratinocyte migration, fibroblast proliferation, angiogenesis, and immune cell recruitment, effects that are entirely separate from their bactericidal function.[3]
Antimicrobial Peptide Dressings
LL-37 and Cathelicidin Derivatives
LL-37, the only human cathelicidin antimicrobial peptide, is a 37-amino-acid molecule that the body naturally produces in wounds. Chronic diabetic ulcers show decreased LL-37 expression compared to healing wounds, suggesting that restoring cathelicidin levels could reactivate stalled healing.
Xi and colleagues demonstrated in 2024 that LL-37 promotes wound healing in diabetic mice by regulating TFEB-dependent autophagy. The peptide enhanced macrophage autophagy, which accelerated the clearance of cellular debris and promoted the transition from inflammatory to proliferative phases. This dual action, antimicrobial activity plus autophagy regulation, makes LL-37 a prototype for peptides that address multiple wound healing barriers simultaneously.[4]
The delivery challenge for LL-37 is that the free peptide degrades rapidly in wound fluid. Su and colleagues solved this in 2019 by electrospinning poly(lactic-co-glycolic acid) nanofiber dressings loaded with 17BIPHE2, a molecularly engineered variant of LL-37. The nanofiber format provided sustained release over days rather than hours. In a biofilm-containing chronic wound model based on type II diabetic mice, these dressings reduced MRSA bacterial load by 5-fold while simultaneously promoting wound closure.[5] For more on how LL-37 functions in immunity, see LL-37's dual role: anti-inflammatory and pro-inflammatory effects and how antimicrobial peptides kill bacteria.
Fumakia and Abbas took a different delivery approach in 2016, encapsulating LL-37 and Serpin A1 (an anti-inflammatory protein) together in poly(lactic-co-glycolic acid) nanoparticles. The co-delivery concept addressed two wound healing barriers at once: infection (LL-37) and excessive inflammation (Serpin A1). The nanoparticles promoted wound healing and synergistically resolved inflammation in diabetic wound models.[6]
Amphibian and Marine-Derived Peptides
Nature has been designing antimicrobial wound peptides for hundreds of millions of years. Amphibian cathelicidins, which protect permeable frog skin from infection in bacteria-rich environments, provide particularly potent templates for wound dressing design.
Cai and colleagues isolated gecko cathelicidin-related antimicrobial peptides in 2021 and demonstrated broad-spectrum activity against wound pathogens. Luo and colleagues characterized a novel anionic cathelicidin from salamanders in the same year. These amphibian-derived peptides often combine antimicrobial potency with wound-healing promotion, features that co-evolved because amphibians depend on rapid wound closure to survive skin injuries in microbially hostile environments.
AI-Designed Wound Peptides
Machine learning is accelerating the development of purpose-built wound healing peptides. Zare-Zardini and colleagues used a genetic algorithm to design Healitide-GP1 in 2025, a novel antibacterial peptide specifically optimized for wound healing applications. Healitide-GP1 achieved 48% and 52% wound closure after 24 hours in vitro (varying by concentration), demonstrated high cytocompatibility with human dermal fibroblasts, and showed strong bactericidal activity against both S. aureus and E. coli. The peptide was designed using computational identification of the structural features most associated with wound healing promotion, representing a shift from discovering natural peptides to engineering them from first principles.[7]
Self-Assembling Peptide Hydrogels
Self-assembling peptides spontaneously form nanofiber networks in physiological conditions, creating hydrogels with over 99% water content that mimic the extracellular matrix. These hydrogels maintain a moist wound environment, provide a scaffold for cell migration and tissue regeneration, and can be loaded with drugs, growth factors, or other bioactive molecules.
RADA16 and PuraDerm
RADA16-I is the most clinically advanced self-assembling peptide for wound care. This 16-amino-acid peptide (Ac-RADARADARADARADA-NH2) self-assembles into beta-sheet nanofibers 10-20 nm in diameter that form a hydrogel within 15-20 seconds upon contact with wound fluid. PuraDerm, the commercial wound dressing based on RADA16-I, has received FDA clearance for use on diabetic foot ulcers, surgical wounds, and pressure sores. Its sister product PuraStat is used as a surgical hemostatic agent.
The RADA16 platform can be functionalized by appending bioactive motifs to the peptide sequence. RADA-PDGF2, a variant incorporating a platelet-derived growth factor mimetic sequence, enhanced skin wound healing in preclinical models by combining the scaffold function of the self-assembling nanofibers with targeted growth factor signaling.
Designer Peptide Hydrogels
Sharma and colleagues demonstrated in 2022 that modifications to the N-terminal and C-terminal residues of self-assembling peptides dramatically affect wound healing outcomes. Their optimized peptide hydrogel achieved 96% wound closure in murine full-thickness wound models, compared to 82% for untreated controls. The hydrogel enhanced collagen deposition, angiogenesis, and granulation tissue formation while maintaining biocompatibility with no cytotoxic effects.[8]
Fan and colleagues developed a pH-sensitive peptide hydrogel in 2024 specifically targeting drug-resistant biofilm-infected diabetic foot ulcers. The hydrogel releases its antimicrobial peptide cargo in response to the acidic pH of infected wound environments, providing targeted drug release where bacterial load is highest. In a diabetic foot ulcer model, this smart hydrogel achieved 97.6% wound closure within 14 days and eliminated drug-resistant biofilm bacteria that had resisted conventional antibiotic treatment.[9]
Wang and colleagues reported a similar pH-responsive co-assembled peptide hydrogel in 2024 that inhibited drug-resistant bacterial infection and promoted wound healing. The co-assembly approach combined antimicrobial and tissue-regenerative peptide sequences in a single self-assembling system, producing a multifunctional dressing from a remarkably simple formulation.[10]
For comprehensive coverage of self-assembling peptide hydrogels in wound care, see peptides for chronic wound healing.
Stage-Adaptive Smart Dressings
The most advanced peptide dressing concepts move beyond static drug release toward dynamic, stage-specific wound management. Ma and colleagues reviewed functionalized peptide hydrogels in 2025, documenting systems that actively shift their behavior as a wound progresses through healing phases.[11]
These programmable hydrogels can provide hemostatic activity in the first minutes after application, release antimicrobial peptides during the initial inflammatory phase, switch to anti-inflammatory signaling as inflammation should resolve, promote angiogenesis during proliferation, and support remodeling during the final maturation phase. The switching mechanism typically relies on degradation-responsive or enzyme-responsive peptide sequences that break down in a predictable order as wound conditions change.
Arciola and colleagues described the broader vision in 2026: smart healing systems for personalized regenerative medicine that integrate tissue regeneration, antimicrobial activity, and real-time sensing of wound status into a single platform. Peptide-based materials are central to this vision because their sequences can be engineered to respond to specific biochemical signals in the wound environment.[12]
GHK-Cu: The Copper Peptide in Wound Repair
Glycyl-L-histidyl-L-lysine copper (GHK-Cu) was one of the earliest peptides studied for wound healing. Buffoni and colleagues demonstrated in 1995 that tripeptide-copper complexes accelerated skin wound healing in guinea pigs. GHK-Cu-treated wounds showed increased hydroxyproline content (a direct measure of collagen synthesis), enhanced semicarbazide-sensitive amine oxidase activity (involved in collagen cross-linking), and improved histological wound structure compared to untreated controls.[13]
GHK-Cu works through a different mechanism than antimicrobial peptides: it modulates gene expression in fibroblasts, upregulating genes involved in extracellular matrix production, growth factor synthesis, and tissue remodeling. The copper ion in the complex is essential for its activity, as it participates in enzymatic reactions that cross-link collagen fibers and stabilize new tissue. For the full evidence review, see GHK-Cu in wound repair.
GLP-1 Agonists and Diabetic Wound Healing
An unexpected entrant in the wound healing peptide space is GLP-1 receptor agonists, the blockbuster diabetes and obesity drugs. Zhang and colleagues demonstrated in 2024 that liraglutide promotes diabetic wound healing through the Myo1c/Dock5 signaling pathway. In streptozotocin-induced diabetic mice, liraglutide treatment accelerated wound closure by enhancing fibroblast migration, angiogenesis, and extracellular matrix deposition. The mechanism involves activation of the small GTPase Rac1, which reorganizes the actin cytoskeleton to enable cell migration into the wound bed.[14]
This finding is relevant because over 500 million people worldwide have diabetes, and diabetic wounds represent one of the largest unmet needs in wound care. If GLP-1 agonists promote wound healing through direct tissue effects beyond glycemic control, then the hundreds of millions of diabetes patients already taking these drugs may be receiving an incidental wound healing benefit. The clinical question is whether topical or local delivery of GLP-1 agonists to wound sites could provide targeted healing promotion. For related coverage, see diabetic wound healing: where peptide research offers hope.
Neuropeptides in Wound Healing
Substance P, a neuropeptide released by sensory nerve endings in the skin, plays a direct role in wound healing that is often overlooked. Leal and colleagues demonstrated in 2015 that Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. In diabetic wound models, Substance P treatment shifted macrophages from the pro-inflammatory M1 phenotype to the pro-healing M2 phenotype, a critical transition that is impaired in diabetic wounds.[15]
This finding connects wound healing to the nervous system in a clinically relevant way. Diabetic neuropathy, which destroys sensory nerve fibers in the skin, reduces local Substance P levels. The loss of neuropeptide signaling may explain, in part, why diabetic wounds heal poorly: the nerve fibers that would normally release pro-healing peptides into the wound bed have degenerated. Restoring neuropeptide levels through exogenous delivery could address a root cause of diabetic wound healing failure rather than just its symptoms.
Delivery Platforms
The biological activity of wound healing peptides is only useful if the peptide reaches the wound bed in active form, at therapeutic concentrations, for a duration matched to the healing process. Several delivery platforms have been developed specifically for peptide wound dressings.
| Platform | Advantages | Limitations | Example |
|---|---|---|---|
| Electrospun nanofibers | High surface area, sustained release, structural scaffold | Fragile, complex manufacturing | LL-37/17BIPHE2 PLGA nanofibers |
| Self-assembling hydrogels | Rapid gelation, ECM-mimicking, injectable | Limited mechanical strength | RADA16/PuraDerm |
| pH-responsive hydrogels | Targeted release at infection sites | Narrow pH response window | Peptide/carboxymethyl chitosan gels |
| Nanoparticle encapsulation | Protection from enzymatic degradation | Burst release risk | LL-37/Serpin A1 PLGA nanoparticles |
| Peptide-tethered dressings | Contact-mediated activity, no release needed | Limited to surface effects | Covalently bonded AMP dressings |
Each platform addresses a different delivery challenge. Nanofibers provide a physical scaffold that promotes cell migration while releasing peptides over days. Self-assembling hydrogels conform to irregular wound geometries and can be applied as liquids that gel in situ. pH-responsive systems target drug release specifically to infected zones within a wound. Nanoparticle encapsulation protects peptides from the proteases abundant in chronic wound fluid. Tethered peptides, covalently bonded to the dressing surface, kill bacteria on contact without releasing any molecule into the wound, eliminating concerns about systemic absorption.
Clinical Status and Regulatory Landscape
The gap between preclinical promise and clinical reality remains the central challenge for peptide wound dressings. Among the approaches discussed:
FDA-cleared products: PuraDerm (RADA16-I self-assembling peptide) is cleared for diabetic foot ulcers, surgical wounds, and pressure sores. PuraStat is used as a hemostatic agent. These represent the most clinically advanced peptide wound care products.
In clinical trials: Several antimicrobial peptide candidates have entered early clinical testing for wound indications. Omiganan (a cathelicidin derivative) reached Phase III trials as a topical antimicrobial. The clinical data for AMP-based dressings specifically (as opposed to topical AMP solutions) remains limited. A 2023 clinical investigation of an antimicrobial peptide hydrogel wound dressing on intact human skin showed significant reduction in skin bioburden (from 1,200 CFU/cm2 to 23 CFU/cm2 over 3 hours) with no cytotoxicity, irritation, or sensitization.
Preclinical/early development: Self-assembling peptide hydrogels beyond RADA16, pH-responsive peptide systems, GLP-1 agonist wound therapies, and AI-designed peptides like Healitide-GP1 remain in preclinical stages.
The regulatory pathway for peptide wound dressings is complicated by their dual nature: they are both a medical device (the dressing) and contain a biologically active drug (the peptide). Products that claim only structural/barrier functions (like PuraDerm) can pursue device clearance. Products making drug claims (infection treatment, healing acceleration) face the longer and more expensive drug approval process. For context on antimicrobial peptides as alternatives to antibiotics more broadly, see antimicrobial peptides as alternatives to antibiotics.
Limitations and Open Questions
Stability in wound fluid. Many antimicrobial peptides lose activity in the protease-rich, high-salt environment of chronic wound fluid. The nanofiber and nanoparticle encapsulation strategies described above address this, but each adds manufacturing complexity and cost.
Cost of goods. Synthetic peptide production remains expensive compared to small-molecule antibiotics. A nanofiber dressing loaded with an engineered cathelicidin variant costs orders of magnitude more to manufacture than a silver-containing foam dressing. Whether the clinical benefits justify the cost differential has not been established in health-economic analyses.
Translation from rodent models. The majority of wound healing data comes from mice, whose skin heals primarily by contraction (pulling wound edges together) rather than re-epithelialization (growing new skin across the wound bed), which is the dominant mechanism in humans. Porcine wound models better replicate human healing, but most peptide dressing studies have not yet progressed to pig models.
Biofilm penetration. Chronic wound biofilms are dense polymicrobial communities enclosed in extracellular matrix. While antimicrobial peptides can disrupt biofilms more effectively than many antibiotics, the efficiency of peptide penetration into mature, thick biofilms varies substantially by peptide sequence and biofilm composition.
Long-term resistance. Bacteria develop resistance to antimicrobial peptides at a lower rate than to conventional antibiotics, but resistance is not impossible. Chromosomal mutations affecting membrane lipid composition and proteolytic enzymes that degrade AMPs have been documented in laboratory evolution experiments. Whether these resistance mechanisms would emerge in clinical wound care settings with chronic peptide exposure is unknown.
Species specificity. Antimicrobial peptides evolved in specific host organisms. The selectivity that makes human LL-37 safe for human tissues may not translate perfectly when using amphibian or marine-derived peptides on human wounds. Cytotoxicity testing has been favorable for most studied peptides, but long-term safety data for non-human-derived wound peptides in clinical use do not exist.
The Bottom Line
Peptide-based wound dressings span four functional categories: antimicrobial peptides that kill bacteria through membrane disruption while promoting tissue repair; self-assembling peptides that form extracellular matrix-mimicking scaffolds; growth factor and signaling peptides that directly stimulate healing pathways; and neuropeptides that modulate inflammation and immune cell behavior. One product (PuraDerm, based on the self-assembling peptide RADA16-I) has reached FDA clearance, while antimicrobial peptide nanofibers, pH-responsive hydrogels, and AI-designed wound peptides remain in preclinical development. The core advantage over conventional dressings is multifunctionality: a single peptide can simultaneously fight infection, reduce inflammation, and promote tissue regeneration through mechanisms that bacteria are unlikely to develop resistance against.